Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Homatropaire
(United States) [Available]Synonyms :
Class :
Anticholinergic Agent and Mydriatic
Brand Name :
Homatropaire
(United States) [Available]Synonyms :
Class :
Anticholinergic Agent and Mydriatic
Dosage Forms & Strengths
Solution-Ophthalmic, as hydrobromide, methylbromide
5% (5 ml)
2%
Dosage Forms & Strengths
Solution-Ophthalmic, as hydrobromide, methylbromide
5% (5 ml)
2%
it increases the effect of anticholinergic agents
they increase the anticholinergic effect of tiotropium
anticholinergic agents increase the efficacy of cimetropium
anticholinergic agents increase the effect of constipation of eluxadoline
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
anticholinergic agents increase the ulcer-producing effect of potassium chloride
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
May enhance the tachycardic effect
May enhance the tachycardic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may increase the risk of adverse effects of opioid agonists
may increase the risk of adverse effects of opioid agonists
may increase the risk of adverse effects of opioid agonists
may increase the risk of adverse effects of opioid agonists
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effect of other cholinergic antagonists
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the toxicity of glucagon
anticholinergic agents decrease the efficacy of itopride
it increases the toxicity of anticholinergic agents
anticholinergic agents diminish the absorption of nitroglycerin
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents decrease the efficacy of secretin methacholine
Adverse drug reactions:
Frequency not Defined
Blurred vision
conjunctivitis
intraocular pressure
ocular exudate photophobia
Pregnancy warnings:
AU TGA pregnancy category: B2
US FDA pregnancy category: C
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: homatropine
Pronunciation: hoe-ma-TROE-peen
Why do we use homatropine?
homatropine belongs to the class Anticholinergic Agent and subclass Mydriatic used to treat uveitis and refraction. And this helps in dilating the pupil.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
